[go: up one dir, main page]

WO2008034623A3 - Médicament destiné à la prophylaxie, au traitement ou au diagnostic de maladies ischémiques - Google Patents

Médicament destiné à la prophylaxie, au traitement ou au diagnostic de maladies ischémiques Download PDF

Info

Publication number
WO2008034623A3
WO2008034623A3 PCT/EP2007/008215 EP2007008215W WO2008034623A3 WO 2008034623 A3 WO2008034623 A3 WO 2008034623A3 EP 2007008215 W EP2007008215 W EP 2007008215W WO 2008034623 A3 WO2008034623 A3 WO 2008034623A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
diagnosis
treatment
medicament
ischaemic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/008215
Other languages
German (de)
English (en)
Other versions
WO2008034623A2 (fr
Inventor
Holger Eltzschig
Tobias Eckle
Almut Grenz
Melanie Hart
Hartmut Osswald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eberhard Karls Universitaet Tuebingen
Original Assignee
Eberhard Karls Universitaet Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eberhard Karls Universitaet Tuebingen filed Critical Eberhard Karls Universitaet Tuebingen
Publication of WO2008034623A2 publication Critical patent/WO2008034623A2/fr
Publication of WO2008034623A3 publication Critical patent/WO2008034623A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03005—5'-Nucleotidase (3.1.3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un médicament destiné à la prophylaxie, au traitement ou au diagnostic de maladies ischémiques, des procédés pour diagnostiquer chez un être vivant une prédisposition à souffrir d'une maladie ischémique ou une maladie ischémique, ainsi qu'une composition pharmaceutique ou diagnostique.
PCT/EP2007/008215 2006-09-20 2007-09-20 Médicament destiné à la prophylaxie, au traitement ou au diagnostic de maladies ischémiques Ceased WO2008034623A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006046410.9 2006-09-20
DE102006046410A DE102006046410A1 (de) 2006-09-20 2006-09-20 Arzneimittel zur Prophylaxe oder Behandlung oder Diagnostik von ischämischen Krankheiten

Publications (2)

Publication Number Publication Date
WO2008034623A2 WO2008034623A2 (fr) 2008-03-27
WO2008034623A3 true WO2008034623A3 (fr) 2008-05-08

Family

ID=39092850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/008215 Ceased WO2008034623A2 (fr) 2006-09-20 2007-09-20 Médicament destiné à la prophylaxie, au traitement ou au diagnostic de maladies ischémiques

Country Status (2)

Country Link
DE (1) DE102006046410A1 (fr)
WO (1) WO2008034623A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU839495A1 (ru) * 1979-04-03 1981-06-23 Винницкий Медицинский Институт Им.H.И.Пирогова Способ дифференциальной диагно-СТиКи РЕВМАТичЕСКиХ пОРОКОВ иишЕМичЕСКОй бОлЕзНи СЕРдцА, ОСлОж-НЕННыХ МЕРцАТЕльНОй АРиТМиЕй
WO2001011949A1 (fr) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Cd39/ecto-adpase servant a traiter des troubles thrombotiques et ischemiques
WO2003105666A2 (fr) * 2002-06-12 2003-12-24 Biogen, Inc. Procede de traitement des lesions consecutives a la perfusion ischemique au moyen des antagonistes de recepteurs d'adenosine
WO2005040155A1 (fr) * 2003-10-02 2005-05-06 Almirall Prodesfarma, S.A. Derives de pyrimidin-2-amine et utilisation de ceux-ci en tant qu'antagonistes du recepteur de l'adenosine a2b

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023459A1 (fr) * 1998-10-16 2000-04-27 Immunex Corporation Inhibiteurs de l'activation et du recrutement plaquettaires
DE19947154A1 (de) * 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
US7390485B2 (en) * 2004-02-27 2008-06-24 Apt Therapeutics, Inc. Design and therapeutic use of adpase enhanced apyrases
ES2732071T3 (es) * 2005-04-01 2019-11-20 Univ Florida Biomarcadores de lesiones hepáticas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU839495A1 (ru) * 1979-04-03 1981-06-23 Винницкий Медицинский Институт Им.H.И.Пирогова Способ дифференциальной диагно-СТиКи РЕВМАТичЕСКиХ пОРОКОВ иишЕМичЕСКОй бОлЕзНи СЕРдцА, ОСлОж-НЕННыХ МЕРцАТЕльНОй АРиТМиЕй
WO2001011949A1 (fr) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Cd39/ecto-adpase servant a traiter des troubles thrombotiques et ischemiques
WO2003105666A2 (fr) * 2002-06-12 2003-12-24 Biogen, Inc. Procede de traitement des lesions consecutives a la perfusion ischemique au moyen des antagonistes de recepteurs d'adenosine
WO2005040155A1 (fr) * 2003-10-02 2005-05-06 Almirall Prodesfarma, S.A. Derives de pyrimidin-2-amine et utilisation de ceux-ci en tant qu'antagonistes du recepteur de l'adenosine a2b

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUCKELBERGER O ET AL: "BENEFICIAL EFFECTS OF CD39/ECTO-NUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE-I IN MURINE INTESTINAL ISCHEMIA-REPERFUSION INJURY", THROMBOSIS AND HAEMOSTASIS, STUTTGART, DE, vol. 91, no. 3, 2004, pages 576 - 586, XP008034526, ISSN: 0340-6245 *

Also Published As

Publication number Publication date
DE102006046410A1 (de) 2008-03-27
WO2008034623A2 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2010144721A3 (fr) Systèmes modèles et régimes de traitement pour un traitement de maladies neurologiques
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
WO2008096012A3 (fr) Conjugué multimère
PH12013500892B1 (en) Composition for use in the prevention and\or treatment of skin conditions and skin diseases
WO2008137758A3 (fr) Lipides d'acides aminés et leurs utilisations
BRPI0909894A2 (pt) "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
WO2008131056A3 (fr) Préparations monoeximiques a libération soutenue d'analgésiques opioïdes et non opioïdes
WO2010057112A3 (fr) Variants génétiques intervenant dans la cognition humaine et leurs procédés d'utilisation comme cibles diagnostiques et thérapeutiques
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
WO2008007211A8 (fr) Composés de carboxyamide bicycliques à n-bicycloalkyle substitué
WO2007106577A3 (fr) Utilisation de la gelsoline pour traiter la sclérose en plaques et pour diagnostiquer des maladies neurologiques
WO2010003992A8 (fr) Combinaison d'un antagoniste de c-met et d'un composé aminohétéroaryle pour le traitement d'un cancer
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
IL197575A (en) A method for removing adult stem cells from the blood, using them to prepare drugs for the treatment of lesions, and a medical preparation containing these adult GES cells
WO2008075040A3 (fr) Agents d'imagerie in vivo
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
WO2010033773A3 (fr) Utilisations diagnostiques, pronostiques et thérapeutiques de mir dans des voies adaptatives et/ou des voies pathologiques
WO2010064248A3 (fr) Procédés de diagnostic et de traitement des maladies des motoneurones
WO2010004283A3 (fr) Thérapie
EP2305316A3 (fr) Glycopeptides diphosphorylés pour l'imagérie de la fibrose
WO2007109733A3 (fr) Marqueurs de diagnostic et de pronostic et strategies de traitement de la sclerose en plaques
WO2007098967A3 (fr) Composés ciblant les récepteurs sigma
WO2007120252A3 (fr) Récepteur soluble humain du facteur m-csf et utilisations de celui-ci
EP2005194A4 (fr) Procédés utilisant de l'hémoglobine pour la prophylaxie, le diagnostic et/ou le traitement de troubles de la rétine
WO2009004914A1 (fr) Sonde de tep ayant un groupe alcoxy substitué par un atome de fluor et un groupe hydroxy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07818305

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07818305

Country of ref document: EP

Kind code of ref document: A2